Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC

EP. 1: EGFR-Mutant NSCLC: Navigating an Increasingly Complex Treatment Landscape

April 25th 2025

Panelists discuss the increasing complexity in treatment decision-making for EGFR-mutant non–small cell lung cancer (NSCLC) with multiple frontline options now available.

EP. 2: MARIPOSA OS Data: Shaping Frontline Treatment in EGFR-Mutant NSCLC

April 25th 2025

Panelists discusses how the MARIPOSA trial demonstrated significant survival improvement with amivantamab plus lazertinib versus osimertinib alone in EGFR-mutant NSCLC, showing a hazard ratio of 0.75 and an expected 12-month survival benefit that could potentially change the natural history of this disease.

EP. 3: Overall Survival as a Driver of 1L EGFRm NSCLC Treatment Selection

May 2nd 2025

Panelists discuss how overall survival is an important but not the only consideration in treatment decision-making, with factors such as patient characteristics, disease burden, and quality of life also being critical.

EP. 4: Understanding OS Through 2 Lenses: Patients and Providers in EGFRm NSCLC

May 2nd 2025

Panelists discuss how health care providers and patients view survival differently, with providers being more data driven and patients focusing on living with minimal symptoms and maintaining quality of life.

EP. 5: Balancing Survival and Quality of Life in 1L EGFRm NSCLC Treatment Decisions

May 2nd 2025

Panelists discuss how treatment choice involves weighing quality of life against treatment burden, considering factors such as hospital visits for infusions vs oral medications at home.

EP. 6: Translating OS Data Into Patient Conversations: Balancing Benefit and Burden

May 2nd 2025

Panelists discuss how explaining survival benefits to patients must be tailored to individual goals and expectations, with many patients having specific life milestones they hope to reach.

EP. 7: Balancing Clinical and Patient-Centered Factors in 1L EGFRm NSCLC Treatment

May 2nd 2025

Panelists discuss how patient-centered factors are crucial in shared decision-making for first-line (1L) treatment, with a potential default approach of offering combination therapy with an option to choose osimertinib monotherapy.

EP. 8: Impact of Disease Characteristics on 1L Treatment Decisions in EGFRm NSCLC

May 2nd 2025

Panelists discuss how disease characteristics such as central nervous system (CNS) metastases can influence treatment decisions, with both FLAURA2 and MARIPOSA trials showing superior outcomes for patients with brain metastases when using combination therapies.

EP. 9: Weighing QoL and Toxicity in 1L EGFRm NSCLC Treatment Decisions

May 2nd 2025

Panelists discuss how quality-of-life (QoL) considerations and individual toxicity profiles significantly impact first-line (1L) treatment decisions, with different regimens having distinct adverse effect profiles.

EP. 10: FLAURA2 Maintenance: Key Strategies for Treatment Optimization and Patient Monitoring

May 2nd 2025

Panelists discuss how FLAURA2 maintenance therapy strategies involve monitoring patients for toxicities and implementing dose modifications or schedule adjustments to improve tolerability.